USANA Health Sciences, Inc. (NYSE:USNA) Director Myron W. Wentz sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $56.59, for a total transaction of $2,263,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of USANA Health Sciences, Inc. (USNA) traded up 1.29% on Friday, reaching $58.80. 120,279 shares of the company were exchanged. The company’s 50-day moving average price is $61.41 and its 200 day moving average price is $60.57. USANA Health Sciences, Inc. has a 12 month low of $52.55 and a 12 month high of $75.00. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 15.27 and a beta of 1.10.
USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, July 25th. The company reported $0.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.08. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The firm had revenue of $257.10 million for the quarter, compared to the consensus estimate of $273.61 million. During the same quarter in the previous year, the business posted $2.07 EPS. The firm’s revenue for the quarter was down .5% compared to the same quarter last year. On average, equities research analysts expect that USANA Health Sciences, Inc. will post $3.79 EPS for the current year.
USANA Health Sciences declared that its board has initiated a stock repurchase program on Tuesday, July 25th that permits the company to buyback $64.60 million in shares. This buyback authorization permits the company to reacquire up to 46% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its shares are undervalued.
A number of research analysts recently issued reports on USNA shares. Pivotal Research decreased their price objective on shares of USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating for the company in a report on Wednesday, July 26th. BidaskClub upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, June 13th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its position in USANA Health Sciences by 124.7% in the first quarter. Victory Capital Management Inc. now owns 2,117 shares of the company’s stock valued at $122,000 after buying an additional 1,175 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in USANA Health Sciences by 13.1% in the second quarter. BNP Paribas Arbitrage SA now owns 2,111 shares of the company’s stock valued at $135,000 after buying an additional 245 shares during the last quarter. Creative Planning raised its position in USANA Health Sciences by 528.0% in the second quarter. Creative Planning now owns 2,512 shares of the company’s stock valued at $161,000 after buying an additional 2,112 shares during the last quarter. SG Americas Securities LLC purchased a new position in USANA Health Sciences during the second quarter valued at about $162,000. Finally, Nine Chapters Capital Management LLC purchased a new position in USANA Health Sciences during the first quarter valued at about $207,000. Hedge funds and other institutional investors own 43.90% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.